- Talazoparib Tosylate
-
-
2026-06-12
- CAS:1373431-65-2
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
|
| | (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate Basic information |
| Product Name: | (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate | | Synonyms: | (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate;BMN-673 ts;BMN-673;BMN673;BMN 673;CS-2862;(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido(4,3,2-de)phthalazin-3-one MONO(4-methylbenzenesulfonate);Talazoparib tosylate (BMN 673ts);BMN673; BMN673; BMN-673; L;(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one 4-methylbenzenesulfonate | | CAS: | 1373431-65-2 | | MF: | C26H22F2N6O4S | | MW: | 552.56 | | EINECS: | | | Product Categories: | | | Mol File: | 1373431-65-2.mol | ![(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate Structure](CAS/20180703/GIF/1373431-65-2.gif) |
| | (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate Chemical Properties |
| Melting point | >281°C (dec.) | | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | | solubility | Acetone (Slightly, Heated, Sonicated), DMSO (Slightly), Methanol (Slightly) | | form | Solid | | color | Off-White to Pale Yellow | | Stability: | Hygroscopic |
| | (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate Usage And Synthesis |
| Uses | Talazoparib Tosylate is Quinoline derivative used for treating non-small cell lung cancer. | | in vivo | Talazoparib is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxylmethyl cellulose. Oral administration of Talazoparib elicits remarkable antitumor activity; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency are profoundly sensitive to oral Talazoparib treatment at well-tolerated doses in mice. Synergistic or additive antitumor effects are also found when Talazoparib is combined with temozolomide, SN38, or platinum drugs[1]. |
| | (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate Preparation Products And Raw materials |
|